Sepede Gianna, Martinotti Giovanni, Gambi Francesco, Salerno Rosa Maria, Di Giannantonio Massimo
Department of Neuroscience and Imaging, Chair of Psychiatry, G d'Annunzio University of Chieti, Chieti, Italy.
Clin Neuropharmacol. 2013 Jan-Feb;36(1):31-3. doi: 10.1097/WNF.0b013e318279ee1f.
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome, characterized by depressive, anxious, and somatic symptoms, associated to a significant reduction in social functioning and quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and oral contraceptives show a substantial effectiveness in PMDD, a wide percentage of women affected by PMDD do not respond to those first-line treatments. We present the case of a 42-year-old woman, affected by a disabling form of PMDD, who partially responded to an SSRI treatment and significantly improved after an add-on therapy with lamotrigine. We therefore suggest that lamotrigine may be an efficacious and safe augmentation strategy in severe PMDD cases showing unsatisfactory or partial response to SSRI treatments.
经前烦躁障碍（PMDD）是经前综合征的一种严重形式，其特征为抑郁、焦虑和躯体症状，与社交功能和生活质量的显著下降有关。尽管选择性5-羟色胺再摄取抑制剂（SSRIs）和口服避孕药在PMDD中显示出显著疗效，但很大一部分受PMDD影响的女性对这些一线治疗无反应。我们报告了一例42岁患有致残性PMDD的女性病例，该患者对SSRI治疗有部分反应，在加用拉莫三嗪治疗后有显著改善。因此，我们认为拉莫三嗪对于对SSRI治疗反应不佳或部分反应的严重PMDD病例可能是一种有效且安全的增效策略。
